News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Union Release: New Study Shows Smoking Tobacco Doubles Risk Of Recurrent Tuberculosis


3/24/2014 12:06:14 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

24 March 2014 – Research published today provides critical new insight on the harmful links between smoking tobacco and developing tuberculosis (TB). Regular tobacco smoking doubles the risk that people who have been successfully treated for TB will develop TB again—a condition known as “recurrent” TB. The study is the most robust ever conducted into how smoking tobacco increases the risk of recurrent TB. It appears in the April issue of the International Journal of Tuberculosis and Lung Disease.

“More than ever before, we understand how tobacco harms people who have already been successfully treated for TB,” said Dr Chung-Yeh Deng of National Yang-Ming University in Taipei , an author of the study. “No one should undergo the long, complex treatment for TB only to unknowingly place themselves at heightened risk of getting the disease again. With this research we can inform national tobacco control policies and educate patients about the risks that smoking tobacco poses.”

The researchers followed a large sample of 5,567 TB patients in Taiwan, each of whom had TB confirmed through bacteriologic testing and went on to successfully complete TB treatment. Of those patients, 1.5 percent developed a recurrent case of TB, with regular tobacco smokers twice as likely to develop recurrent TB compared with former smokers and with individuals who had never smoked tobacco. Regular tobacco smokers were defined as individuals who smoked 10 or more cigarettes—equivalent to half a pack—per day.

“Until this study was published, we didn’t have a clear sense of how smoking tobacco posed risks to TB patients who have put in the hard work of completing their treatment. This is a robust study with important implications for patients, public health programmes and policy-makers alike,” said Dr Paula Fujiwara, Scientific Director of the International Union Against Tuberculosis and Lung Disease (The Union), which publishes the journal.

The research was announced on 24 March to coincide with World TB Day, which marks the anniversary of Prof Robert Koch’s discovery of the bacteria that cause tuberculosis in Berlin. More than a century later, Koch’s discovery is still considered among the most revolutionary in the history of medicine, since it paved the way to finding a cure for the disease known in the 19th century as “The White Plague”.

“You often see tuberculosis still referred to as an ‘ancient’ disease, but this study is further evidence that TB is a fully modern illness that is impacting people in new ways,” said José

Luis Castro, Interim Executive Director of The Union. “Unless we adapt our TB control strategies to respond to newly ascertained risks, such as smoking tobacco, the global rise in diabetes, and the overcrowding we see in cities as the world urbanises, we will always remain two steps behind the bacteria that cause this disease.”

Open access to the full study is available at http://www.ingentaconnect.com/content/iuatld/ijtld/pre-prints on 24 March at 10.30 CET and at its permanent position later on that day: http://www.ingentaconnect.com/content/iuatld/ijtld/2014/00000018/00000004/art000 21

About Tuberculosis

Tuberculosis is an infectious disease that is transmitted from person to person through the air, typically through coughing or sneezing. According to the World Health Organization, in 2012 an estimated 8.6 million people became sick with TB, and 1.3 million people died from TB or TB-related causes—more deaths than any other infectious disease except HIV/AIDS. Current treatment regimens require a patient to take several drugs for at least six months and up to two years or more for some drug-resistant cases.

About The International Union Against Tuberculosis and Lung Disease (The Union)

The mission of The Union is to bring innovation, expertise, solutions and support to address health challenges in low- and middle-income populations. With nearly 15,000 members and subscribers from 150 countries, The Union has its headquarters in Paris and offices in the Africa, Asia Pacific, Europe, Latin America, North America and South-East Asia regions. Its scientific departments focus on tuberculosis and HIV, lung health and non- communicable diseases, tobacco control and research. Last week, The Union was awarded a new grant to increase detection and treatment of TB among the urban poor living in major cities in Uganda. This award to The Union’s SPARK-TB project was provided by UNITAID through support from the Government of Canada.

For more information, please visit www.theunion.org

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES